The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Subjects With Non-Alcoholic Fatty Liver Disease: A Randomized Open-Label Clinical Trial

Authors Information
Article Notes and Dates
To Cite : Jamali R, Mofid A, Vahedi H, Farzaneh R, Dowlatshahi S. et al. The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Subjects With Non-Alcoholic Fatty Liver Disease: A Randomized Open-Label Clinical Trial, Hepat Mon. 2013 ;13(12):e14679. doi: 10.5812/hepatmon.14679.
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Stalke P, Al-Soud WA, Bielawski KP, Bakowska A, Trocha H, Stepinski J, et al. Detection of Helicobacter species in liver and stomach tissues of patients with chronic liver diseases using polymerase chain reaction-denaturing gradient gel electrophoresis and immunohistochemistry. Scand J Gastroenterol. 2005; 40(9): 1032-41[DOI][PubMed]
  • 2. Pirouz T, Zounubi L, Keivani H, Rakhshani N , Hormazdi M. Detection of Helicobacter pylori in paraffin-embedded specimens from patients with chronic liver diseases, using the amplification method. Dig Dis Sci. 2009; 54(7): 1456-9
  • 3. Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, Engin D, et al. Identification of Helicobacter species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases. Eur J Gastroenterol Hepatol. 2008; 20(1): 33-6[DOI][PubMed]
  • 4. Huang Y, Fan XG, Wang ZM, Zhou JH, Tian XF, Li N. Identification of helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J Clin Pathol. 2004; 57(12): 1273-7[DOI][PubMed]
  • 5. Pellicano R, Menard A, Rizzetto M, Megraud F. Helicobacter species and liver diseases: association or causation? Lancet Infect Dis. 2008; 8(4): 254-60[DOI][PubMed]
  • 6. Taylor NS, Fox JG, Yan L. In-vitro hepatotoxic factor in Helicobacter hepaticus, H. pylori and other Helicobacter species. J Med Microbiol. 1995; 42(1): 48-52[PubMed]
  • 7. Fukuda Y, Bamba H, Okui M, Tamura K, Tanida N, Satomi M, et al. Helicobacter pylori infection increases mucosal permeability of the stomach and intestine. Digestion. 2001; 63 Suppl 1: 93-6[PubMed]
  • 8. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, et al. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol. 2008; 103(12): 3005-10[DOI][PubMed]
  • 9. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, et al. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter. 2009; 14(5): 144-50[DOI][PubMed]
  • 10. Nwokolo CU, Freshwater DA, O'Hare P, Randeva HS. Plasma ghrelin following cure of Helicobacter pylori. Gut. 2003; 52(5): 637-40[PubMed]
  • 11. Wu MS, Lee WJ, Wang HH, Huang SP, Lin JT. A case-control study of association of Helicobacter pylori infection with morbid obesity in Taiwan. Arch Intern Med. 2005; 165(13): 1552-5[DOI][PubMed]
  • 12. Jamali R, Pourshams A, Amini S, Deyhim MR, Rezvan H, Malekzadeh R. The upper normal limit of serum alanine aminotransferase in Golestan Province, northeast Iran. Arch Iran Med. 2008; 11(6): 602-7[PubMed]
  • 13. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008; 14(18): 2867-71[PubMed]
  • 14. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009; 137(3): 865-72[DOI][PubMed]
  • 15. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis. 2011; 12(1): 38-44[DOI][PubMed]
  • 16. Suzuki A, Binks M, Sha R, Wachholtz A, Eisenson H, Diehl AM. Serum aminotransferase changes with significant weight loss: sex and age effects. Metabolism. 2010; 59(2): 177-85[DOI][PubMed]
  • 17. Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther. 2001; 15(3): 411-6[PubMed]
  • 18. Razavizade M, Jamali R, Arj A, Talari H. Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2012; 11(5): 513-20[PubMed]
  • 19. Jonaitis LV, Kiudelis G, Kupcinskas L. Evaluation of a novel 14C-urea breath test "Heliprobe" in diagnosis of Helicobacter pylori infection. Medicina (Kaunas). 2007; 43(1): 32-5[PubMed]
  • 20. Hashemipour M, Soghrati M, Malek Ahmadi M, Soghrati M. Anthropometric indices associated with dyslipidemia in obese children and adolescents: a retrospective study in isfahan. ARYA Atheroscler. 2011; 7(1): 31-9[PubMed]
  • 21. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27(6): 1487-95[PubMed]
  • 22. Dogan Z, Filik L, Ergul B, Sarikaya M, Akbal E. Association between Helicobacter pylori and liver-to-spleen ratio: a randomized-controlled single-blind study. Eur J Gastroenterol Hepatol. 2013; 25(1): 107-10[DOI][PubMed]
  • 23. Ponzetto A, Pellicano R, Leone N, Cutufia MA, Turrini F, Grigioni WF, et al. Helicobacter infection and cirrhosis in hepatitis C virus carriage: is it an innocent bystander or a troublemaker? Med Hypotheses. 2000; 54(2): 275-7[DOI][PubMed]
  • 24. Leone N, Pellicano R, Brunello F, Cutufia MA, Berrutti M, Fagoonee S, et al. Helicobacter pylori seroprevalence in patients with cirrhosis of the liver and hepatocellular carcinoma. Cancer Detect Prev. 2003; 27(6): 494-7[PubMed]
  • 25. Takuma Y. [Helicobacter pylori infection and liver diseases]. Gan To Kagaku Ryoho. 2011; 38(3): 362-4[PubMed]
  • 26. Polyzos SA, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2013; 62(1): 121-6[DOI][PubMed]
  • 27. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011; 15(9): 1090-5[PubMed]
  • 28. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol. 2003; 38(5): 681-7[PubMed]
  • 29. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51(1): 121-9[DOI][PubMed]
  • 30. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006; 103(33): 12511-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check